We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Designer Drugs May Respond to Genetic Switch

By Biotechdaily staff writers
Posted on 02 Mar 2005
Researchers have found a way to use a genetic switch to control the activity of a specific protein, which could facilitate the development of designer drugs that would only become active in cells expressing a certain gene.

Investigators at the University of California, Los Angeles (UCLA, USA), attached a single strand of DNA to maltose binding protein, a transport protein. More...
Working with a bacterial model, they found that binding a complementary DNA strand--forming double-stranded DNA--caused a change in the mechanical tension of the protein molecule. The alteration in tension was sufficient to transform the protein from an inert to an active state. These findings were published in the January 28, 2005, issue of Physical Review Letters.

"We can switch a protein on and off, and while we have controlled a specific protein, we believe our approach will work with virtually any protein,” said contributing author Dr. Giovanni Zocchi, assistant professor of physics at UCLA. "This research has the potential to start a new approach to protein engineering.”



Related Links:
University of California, Los Angeles

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Aspiration System
VACUSAFE
New
Thyroid Test
Anti-Thyroid EIA Test
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.